Basics Actinium Pharmaceuticals, Inc Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A. IPO Date: January 1, 2003 Sector: Healthcare Industry: Biotech Market Cap: $49.91M Activated in VL: True Average Daily Range Avg Daily Range: $0.15 | 3.50% Avg Daily Range (30 D): $0.04 | 2.69% Avg Daily Range (90 D): $0.05 | 3.26% Institutional Daily Volume Avg Daily Volume: 1.05M Avg Daily Volume (30 D): .14M Avg Daily Volume (90 D): .2M Trade Size Avg Trade Size (Sh.): 445 Avg Trade Size (Sh.) (30 D): 165 Avg Trade Size (Sh.) (90 D): 146 Institutional Trades Total Inst.Trades: 47 Avg Inst. Trade: $1.86M Avg Inst. Trade (30 D): $2.2M Avg Inst. Trade (90 D): $2.2M Avg Inst. Trade Volume: .24M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.11M Avg Closing Trade (30 D): $3.87M Avg Closing Trade (90 D): $3.87M Avg Closing Volume: 431.92K     News May 25, 2025 @ 10:07 PM המועד האחרו×Å... Source: N/A May 25, 2025 @ 10:07 PM ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED L... Source: N/A May 21, 2025 @ 8:00 PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman... Source: Bronstein, Gewirtz & Grossman, Llc May 21, 2025 @ 12:00 AM ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds A... Source: N/A May 19, 2025 @ 11:40 PM ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium ... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $-1.31 $-.22 $-.51 Diluted EPS $-1.31 $-.22 $-.51 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -41.04M $ -6.88M $ -15.94M Operating Income / Loss $ -44.25M $ -7.5M $ -16.64M Cost of Revenue $ $ $ Net Cash Flow $ -13.13M $ M $ M PE Ratio     Splits Aug 11, 2020:   1:30